PDCD1 and neoplasm: Clinical trials of drugs blocking PD-1/PD-L1 (NCT02370498, NCT02494583 and NCT03019588) in GC are currently underway, and the relationship between the objective response/clinical benefit and PD-L1 expression by tumor cells and immune cells will be further investigated and discussed.